These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 31713607)

  • 1. Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics.
    Srivastava S; Deshpande D; Magombedze G; van Zyl J; Cirrincione K; Martin K; Bendet P; Berg A; Hanna D; Romero K; Hermann D; Gumbo T
    J Antimicrob Chemother; 2020 Feb; 75(2):392-399. PubMed ID: 31713607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet!
    Srivastava S; Deshpande D; Magombedze G; Gumbo T
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S359-S364. PubMed ID: 30496465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen.
    Dutta NK; Alsultan A; Gniadek TJ; Belchis DA; Pinn ML; Mdluli KE; Nuermberger EL; Peloquin CA; Karakousis PC
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3910-6. PubMed ID: 23733473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis.
    Xu J; Li SY; Almeida DV; Tasneen R; Barnes-Boyle K; Converse PJ; Upton AM; Mdluli K; Fotouhi N; Nuermberger EL
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30833432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycobacterium tuberculosis sterilizing activity of faropenem, pyrazinamide and linezolid combination and failure to shorten the therapy duration.
    Gumbo T; Sherman CM; Deshpande D; Alffenaar JW; Srivastava S
    Int J Infect Dis; 2021 Mar; 104():680-684. PubMed ID: 33556616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-a-week tigecycline for the treatment of drug-resistant TB.
    Deshpande D; Magombedze G; Srivastava S; Bendet P; Lee PS; Cirrincione KN; Martin KR; Dheda K; Gumbo T
    J Antimicrob Chemother; 2019 Jun; 74(6):1607-1617. PubMed ID: 30820554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB.
    Tweed CD; Wills GH; Crook AM; Amukoye E; Balanag V; Ban AYL; Bateson ALC; Betteridge MC; Brumskine W; Caoili J; Chaisson RE; Cevik M; Conradie F; Dawson R; Del Parigi A; Diacon A; Everitt DE; Fabiane SM; Hunt R; Ismail AI; Lalloo U; Lombard L; Louw C; Malahleha M; McHugh TD; Mendel CM; Mhimbira F; Moodliar RN; Nduba V; Nunn AJ; Sabi I; Sebe MA; Selepe RAP; Staples S; Swindells S; van Niekerk CH; Variava E; Spigelman M; Gillespie SH
    Int J Tuberc Lung Dis; 2021 Apr; 25(4):305-314. PubMed ID: 33762075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges.
    Magombedze G; Pasipanodya JG; Srivastava S; Deshpande D; Visser ME; Chigutsa E; McIlleron H; Gumbo T
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S349-S358. PubMed ID: 30496464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delamanid Kills Dormant Mycobacteria
    Chen X; Hashizume H; Tomishige T; Nakamura I; Matsuba M; Fujiwara M; Kitamoto R; Hanaki E; Ohba Y; Matsumoto M
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis.
    Li SY; Tasneen R; Tyagi S; Soni H; Converse PJ; Mdluli K; Nuermberger EL
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating
    Srivastava S; Cirrincione KN; Deshpande D; Gumbo T
    Front Pharmacol; 2020; 11():616294. PubMed ID: 33542690
    [No Abstract]   [Full Text] [Related]  

  • 13. Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models.
    Tasneen R; Garcia A; Converse PJ; Zimmerman MD; Dartois V; Kurbatova E; Vernon AA; Carr W; Stout JE; Dooley KE; Nuermberger EL
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0239821. PubMed ID: 35315690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.
    Diacon AH; Dawson R; von Groote-Bidlingmaier F; Symons G; Venter A; Donald PR; van Niekerk C; Everitt D; Winter H; Becker P; Mendel CM; Spigelman MK
    Lancet; 2012 Sep; 380(9846):986-93. PubMed ID: 22828481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis.
    Veziris N; Ibrahim M; Lounis N; Andries K; Jarlier V
    PLoS One; 2011 Mar; 6(3):e17556. PubMed ID: 21408613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way.
    Deshpande D; Srivastava S; Nuermberger E; Pasipanodya JG; Swaminathan S; Gumbo T
    Clin Infect Dis; 2016 Nov; 63(suppl 3):S95-S101. PubMed ID: 27742640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moxifloxacin Replacement in Contemporary Tuberculosis Drug Regimens Is Ineffective against Persistent Mycobacterium tuberculosis in the Cornell Mouse Model.
    Liu Y; Pertinez H; Davies GR; Gillespie SH; Coates AR; Hu Y
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis.
    Tasneen R; Williams K; Amoabeng O; Minkowski A; Mdluli KE; Upton AM; Nuermberger EL
    Antimicrob Agents Chemother; 2015 Jan; 59(1):129-35. PubMed ID: 25331697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
    Diacon AH; Dawson R; von Groote-Bidlingmaier F; Symons G; Venter A; Donald PR; van Niekerk C; Everitt D; Hutchings J; Burger DA; Schall R; Mendel CM
    Am J Respir Crit Care Med; 2015 Apr; 191(8):943-53. PubMed ID: 25622149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo.
    Deshpande D; Srivastava S; Nuermberger E; Pasipanodya JG; Swaminathan S; Gumbo T
    Clin Infect Dis; 2016 Nov; 63(suppl 3):S88-S94. PubMed ID: 27742639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.